Given the increasing number of reports regarding the beneficial effects of GH treatment in patients with brain injury and stroke [4, 5, 14, 30–32], as well as its therapeutic potential to treat neurodegenerative diseases [33, 34], it is pertinent to further investigate the interactions between the administration of GH and the expression of endogenous neurotrophic factors that may be involved in local neuroprotection mechanisms. The gene discussed is GH1; the disease is neurodegenerative disease.